Equities researchers at Cowen initiated coverage on shares of Erytech Pharma (NASDAQ:ERYP) in a research note issued to investors on Tuesday. The firm set an “outperform” rating on the stock.

Separately, JMP Securities began coverage on shares of Erytech Pharma in a report on Friday. They issued an “outperform” rating and a $43.00 price objective on the stock.

Erytech Pharma (ERYP) traded up $1.61 during mid-day trading on Tuesday, hitting $29.36. 22,700 shares of the stock traded hands, compared to its average volume of 32,650. The company has a current ratio of 10.67, a quick ratio of 10.65 and a debt-to-equity ratio of 0.03. Erytech Pharma has a fifty-two week low of $24.59 and a fifty-two week high of $29.83.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/erytech-pharma-eryp-coverage-initiated-at-cowen.html.

Erytech Pharma Company Profile

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells.

Receive News & Ratings for Erytech Pharma SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma SA and related companies with MarketBeat.com's FREE daily email newsletter.